1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Cancer Pain Therapeutics Market 2015-2019

Global Cancer Pain Therapeutics Market 2015-2019

  • January 2016
  • -
  • Infiniti Research Limited
  • -
  • 61 pages

About Cancer Pain Therapeutics

Cancer pain can be acute or chronic, depending on its stages and types. Cancer pain is caused by the tumor pressing against bones, nerves, or other organs in an individual's body. Pain control is imperative not only for people who have advanced cancer but also for those whose condition remains stable for years. Pharmaceutical interventions such as non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and adjuvant pain medications are used to treat cancer pain.

Technavio’s analysts forecast the global cancer pain therapeutics market to grow at a CAGR of 9.08% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global cancer pain therapeutics market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of cancer pain.
The market is divided into the following segments based on region:
- Americas: The US, Canada, Mexico, and Brazil
- EMEA: The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
- APAC: Japan, China, Australia, Singapore, South Korea, and India

Technavio's report, Global Cancer Pain Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.

Key vendors
- BioDelivery Sciences
- ProStrakan Group
- Teva Pharmaceuticals
- Yamaha


Other prominent vendors
- Daiichi Sankyo
- Eli-lilly
- Galena Biopharma
- Grunenthal Group
- GW Pharmaceuticals
- Hospira
- Johnson & Johnson
- Meda Pharmaceuticals
- Orexo
- Sanofi
- Sorrento Therapeutics
- WEX Pharmaceuticals

Market driver
- Unmet medical needs
- For a full, detailed list, view our report

Market challenge
- Off-label drug use
- For a full, detailed list, view our report

Market trend
- Increase in awareness
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table Of Contents

Global Cancer Pain Therapeutics Market 2015-2019
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Disease overview
- Understanding the disease
- Signs and symptoms
- Causes of cancer pain
- Assessment of cancer pain
- Treatment
- Epidemiology
PART 06: Pipeline portfolio
- Information on pipeline candidates
PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 08: Market segmentation by drug class
- Opioids
- Non-steroidal anti-inflammatory drugs
- Others
PART 09: Geographical segmentation
- Cancer pain therapeutics market in Americas
- Cancer pain therapeutics market in EMEA
- Cancer pain therapeutics market in APAC
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
- Competitive scenario
- Market analysis 2014
PART 16: Vendor landscape
- Other prominent vendors
PART 17: Key vendor analysis
- BioDelivery Sciences
- ProStrakan
- Teva Pharmaceuticals
PART 18: Appendix
- List of abbreviations
PART 19: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Classification of cancer pain
Exhibit 03: Acute pain syndromes
Exhibit 04: Chronic pain syndromes
Exhibit 05: Causes of pain from cancer
Exhibit 06: Causes of pain from procedures and surgery
Exhibit 07: Causes of pain from other cancer treatments
Exhibit 08: Common causes of pain in cancer patients
Exhibit 09: Cancer pain assessment
Exhibit 10: Types of pain scales
Exhibit 11: Treatment options for cancer pain
Exhibit 12: Commonly used non-opioids for pain management
Exhibit 13: Commonly used adjuvant medicines for cancer pain
Exhibit 14: Management of cancer pain
Exhibit 15: Pipeline molecules for cancer pain therapeutics market
Exhibit 16: Global cancer pain therapeutics market ($ millions)
Exhibit 17: Five forces analysis
Exhibit 18: Global cancer pain therapeutics market by drug class
Exhibit 19: Global cancer pain therapeutics market by geographical segmentation 2014
Exhibit 20: Cancer pain therapeutics market in different regions, 2014-2019 ($ millions)
Exhibit 21: Cancer pain therapeutics market in the Americas 2014-2019 ($ millions)
Exhibit 22: Cancer pain therapeutics market in EMEA 2014-2019 ($ millions)
Exhibit 23: Cancer pain therapeutics market in APAC 2014-2019 ($ millions)
Exhibit 24: Impact of drivers
Exhibit 25: Impact of drivers and challenges
Exhibit 26: BioDelivery Sciences: Key takeaways
Exhibit 27: ProStrakan: Key takeaways
Exhibit 28: Teva Pharmaceuticals: Key takeaways
Exhibit 29: BioDelivery Sciences: Product pipeline
Exhibit 30: Teva Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 31: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 32: Teva Pharmaceuticals: Geographical segmentation by revenue 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.